The HPRA has updated the method of sale and supply of ophthalmological prostaglandin analogues indicated for the reduction of elevated intraocular pressure with open angle glaucoma and ocular hypertension, either alone or in combination with topical beta-blockers. The HPRA has amended the legal supply status of all these products from “product subject to prescription which may not be renewed (A)” to “product subject to prescription which may be renewed (B)”. These products are initiated under specialist case and are intended for repeat use over an extended period with regular monitoring.
A complete list of all eye drops containing prostaglandin analogues on the IPU Product File can be found here. All of these products are now S1B.